During the past trading week (January 20 to 24), a Canadian cannabis producer announced a massive, multi-million dollar influx of cash from a mysterious benefactor.

TMX Group (TSX:X) unveiled a new index that tracks the performance of the biggest cannabis companies on its exchanges, and a pharmaceutical company that specializes in cannabinoid-based medicine enjoyed some major wins for product distribution across Canada.

Here’s a closer look at some of the biggest cannabis news over the week.

Aphria rakes in C$100 million from institutional investors

Aphria (NYSE:APHA,TSX:APHA) said it’s now flush with cash with the news of a C$100 million strategic investment from an undisclosed institutional investor.

The Friday (January 24) announcement said the unnamed institution has agreed to purchase over 14 million units of Aphria at a price of C$7.12 per unit. Each unit is made up of one common share and a half of a purchase warrant. With a warrant, the investor will be able to buy additional common shares at C$9.26 a piece for up two years after the deal closes.

Aphria said it now boasts a cash balance pro forma of almost C$600 million. The company plans to use the new funding to finance international expansion, which has also been helped by the recent receipt of a European Union Good Manufacturing Practices certification from the Malta Medicines Authority for its facility in Leamington, Ontario, on Wednesday.

The money will also go towards working capital and other general corporate needs.

“Given the strength of our leadership team, the continued execution of our strategic plan and the robust opportunities we have for growth in the global cannabis industry, we were able to secure this additional capital from a single investor, a significant endorsement of Aphria in these market conditions,” said CFO Carl Merton in a press release.

The offering, subject to customary closing conditions and regulatory approval, is expected to close on January 31.

At the market open on Friday, Aphria prices were at C$7.85 in Toronto.

S&P/TSX Cannabis Index launches on TSX

On Monday (January 20) TMX Group introduced the S&P/TSX Cannabis Index (TSX:XCAN) onto the Toronto Stock Exchange (TSX).

The new exclusive index tracks 15 of the largest companies listed on the TSX or the TSX Venture Exchange (TSXV) that are “significantly involved in the cannabis market,” TMX Group said in a press release.

Firms on the list run the gamut from juggernauts like Canopy Growth (NYSE:CGC,TSX:WEED) and Aurora Cannabis (NYSE:ACB,TSX:ACB) to smaller companies focused on specialized sections of the supply chain like PharmaCielo (TSXV:PCLO,OTCQX:PCLOF) and MediPharm Labs (TSX:LABS,OTCQX:MEDIF).

The S&P/TSX Cannabis Index follows shortly after TMX launched the S&P/MX International Cannabis Index (TSX:MCAN) late last year. The global version of the index features 22 cannabis companies that list on the New York Stock Exchange and the NASDAQ, as well as the TSX exchanges in Canada.

On Friday, the S&P/TSX Cannabis Index opened at C$230.23.

Tetra Bio Pharma prepares for over-the-counter product distribution in Canada

Consumers in Canada will soon be able to get their hands on cannabinoid-based medicine without a prescription.

Tetra Bio-Pharma (TSXV:TBP,OTCQB:TBPMF) announced on Monday it was bringing its TERPACAN brand of hemorrhoid and back and muscle pain treatments to pharmacies across the country by mid-2020.

The distribution update comes after Tetra was granted two over-the-counter drug identification numbers from Health Canada earlier in January.

Prep work for the company leading up to its nation-wide distribution goals have included locking down undisclosed contracts with manufacturing and sales organizations to ensure the products are quickly developed and marketed.

The Ontario-based drug maker also told investors of a C$10 million bought deal offering on Tuesday (January 21). This round of financing is being completed by investment firm Echelon Wealth Partners, who has agreed to purchase almost 19 million units of Tetra for C$0.53 a piece.

Market updates

An article from MarketWatch found that California-based MedMen Enterprises (CSE:MMEN,OTCQX:MMNFF) is in a scramble for cash as it offers retailers shares of its company as payment for cannabis products.

In an email sent to MarketWatch, MedMen CFO Zeeshan Hyder confirmed that the company has been working with vendors on adjusting payment terms, which has included offering class B non-voting shares in a payment plan to clear outstanding debts.

PharmaCielo signed a distribution deal to send its cannabidiol (CBD) isolate and CBD oil across Europe with the Quebec-based CBD Export Global. As a part of the three year deal, the first shipments are expected to be sent out sometime in 2020.

iAnthus Capital Holdings (CSE:IAN,OTCQX:ITHUF) is now set to enter the Massachusetts cannabis market after being approved to cultivate and process recreational cannabis at its facility in the state.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: MediPharm Labs is a client of the Investing News Network. This article is not paid-for content. 

 BioHarvest Sciences Inc. (CSE: BHSC) (the “Company” or “BioHarvest”) invites its shareholders and the general public to join a Live Video Conference (“Webinar”) on Thursday, January 21st, 2021 at 2:00 PM Eastern Standard Time (11:00 AM Pacific Standard Time). Ilan Sobel, CEO of BHSC, will host the event and discuss progress on Bioharvest’s Growth Plan, which will include highlights of the 2020 milestones achieved, key business capabilities built, and will provide an important overview of 2021 Priorities.

The presentation will be approximately 35 minutes, followed by a live question and answer session.

Keep reading... Show less

World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”), reports that it has sold its 50% interest in Cobra Ventures Inc. (“Cobra”), which sale included all funds previously advanced by World Class to Cobra, to the remaining shareholder of Cobra, for $2,500,000 in cash

An investment group led by Richard Goldstein retains 100% control of Cobra, and its senior secured debenture of Hydrx Farms Ltd. (“Hydrx”), acquired by Cobra in October 2020.

Keep reading... Show less

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Kurt Schmidt, President and Chief Executive Officer, will speak at the 24th Annual CIBC Western Institutional Investor Conference on Friday, January 22, 2021 at 4:10 p.m. EST.

A recording will be available on the Investors section of the Company’s website at https://ir.thecronosgroup.com/events-presentations .

Keep reading... Show less
  • Disease control of root-rot Aphanomyces zoospores in laboratory tests.
  • Outstanding Efficacy: 100% control at economic application rates within 24 hours.
  • Aphanomyces is a soil-borne root-rot disease that destroys peas, lentils, and legume crops.

MustGrow Biologics Corp. (CSE: MGRO) (OTC: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce successful laboratory test results of its patented mustard-derived biopesticide on Aphanomyces euteiches zoospores (“Aphanomyces”) via an independent third party facility: 100% control at economic application rates within 24 hours. MustGrow will now advance to larger scale greenhouse and field tests. Study results and applicability are patent-protected under MustGrow’s existing suite of issued patents.

MustGrow’s remarkably safe and effective organic biopesticide is plant-based – harnessing the mustard seed’s natural defense mechanism to control diseases, pests, and weeds with an organic food-grade biopesticide.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or “the Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced the hiring of CPG industry veteran Ty Gent as the Company’s new Chief Operating Officer (“COO”). As COO, Gent will be responsible for operational consistency and efficiency across markets and implementation of structural enhancements to facilitate scaling.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005322/en/

Keep reading... Show less